Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for what the Company refers to as the "Weber/Cowley methods patent" (U.S. patent application no.11/356,839) which provides coverage for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials.
The details can be read here.
No comments:
Post a Comment